Francisco Javier Salvador-Bofill

Statistics

Publications

Citations

H-Index

Active since

2021

Affiliations

Hospital Universitario de Canarias(Current)

Hospital Clínic de Barcelona

Vall d'Hebron Hospital Universitari

Hospital Clínico Universitario de Valencia

Research Institute Hospital 12 de Octubre

Francisco Javier Salvador-Bofill is an author at Hospital Universitario de Canarias specializing in hormone receptor-positive breast cancer immunotherapy, hormone receptor-positive breast cancer therapy, and medicine.

Publications per year

2021–2024

Publications

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

Mafalda Oliveira, Claudette Falato, Juan Miguel Cejalvo et al. · Annals of Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Tomás Pascual, Mafalda Oliveira, Eva Ciruelos et al. · Frontiers in Oncology · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Fara Brasó‐Maristany, J.M. Ferrero-Cafiero, Claudette Falato et al. · Nature Communications · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

1–3 of 3